These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23513890)

  • 1. [Acute myeloid leukemia].
    Nannya Y; Kurokawa M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():496-500. PubMed ID: 23513890
    [No Abstract]   [Full Text] [Related]  

  • 2. New drugs in acute myeloid leukemia.
    Estey E
    Semin Oncol; 2008 Aug; 35(4):439-48. PubMed ID: 18692694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
    Tallman M
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
    Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
    Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current treatment of acute myeloid leukaemia in adults].
    Telek B; Rejto L; Kiss A; Batár P; Reményi G; Szász R; Ujj ZÁ; Udvardy M
    Orv Hetil; 2012 Feb; 153(7):243-9. PubMed ID: 22318524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 7. Is targeted therapy feasible in acute myelogenous leukemia?
    Konig H; Levis M
    Curr Hematol Malig Rep; 2014 Jun; 9(2):118-27. PubMed ID: 24599573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First new drug approval for AML in 15 years.
    Sheridan C
    Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
    [No Abstract]   [Full Text] [Related]  

  • 9. Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemia.
    Van Echo DA; Lichtenfeld KM; Wiernik PH
    Cancer Treat Rep; 1977 Nov; 61(8):1599-602. PubMed ID: 72605
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular target drugs for AML--current state and prospects for the future].
    Kohgo Y; Inamura J; Shindo M
    Nihon Rinsho; 2014 Jun; 72(6):1063-7. PubMed ID: 25016805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
    Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
    Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
    [No Abstract]   [Full Text] [Related]  

  • 12. [FLT3 inhibitors for acute myeloid leukemia].
    Kiyoi H
    Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-CD33 monoclonal antibody drug conjugate--Gemtuzumab ozogamicin (GO)].
    Usui N
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():215-8. PubMed ID: 25831755
    [No Abstract]   [Full Text] [Related]  

  • 14. Gemtuzumab: time to bring back on the market?
    Foran JM
    Clin Adv Hematol Oncol; 2012 May; 10(5):326-7. PubMed ID: 22706544
    [No Abstract]   [Full Text] [Related]  

  • 15. Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology.
    Stone RM
    Expert Rev Hematol; 2013 Apr; 6(2):127-9. PubMed ID: 23547861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
    Martini V; Minotti C; Breccia M; De Angelis G; Buffolino S; Mariella M; Lo-Coco F; Avvisati G; Cimino G
    Ann Hematol; 2007 Apr; 86(4):295-7. PubMed ID: 17136541
    [No Abstract]   [Full Text] [Related]  

  • 17. [Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
    Brotelle T; Lemal R; Moluçon-Chabrot C; Bay JO; Delaunay J; Guièze R
    Bull Cancer; 2014 Feb; 101(2):211-8. PubMed ID: 24557850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
    Foran JM
    Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
    Hayashi Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
    Ohnishi K
    Rinsho Ketsueki; 2006 Aug; 47(8):717-23. PubMed ID: 16986710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.